Rituximab as monotherapy for the treatment of chronic active antibody-mediated rejection after kidney transplantation.

Details

Ressource 1Download: 29328536_post_print_cover.pdf (782.86 [Ko])
State: Public
Version: Author's accepted manuscript
Serval ID
serval:BIB_C54B7A2AC6FE
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Rituximab as monotherapy for the treatment of chronic active antibody-mediated rejection after kidney transplantation.
Journal
Transplant international
Author(s)
Muller Y.D., Ghaleb N., Rotman S., Vionnet J., Halfon M., Catana E., Golshayan D., Venetz J.P., Aubert V., Pascual M.
ISSN
1432-2277 (Electronic)
ISSN-L
0934-0874
Publication state
Published
Issued date
04/2018
Peer-reviewed
Oui
Volume
31
Number
4
Pages
451-455
Language
english
Notes
Publication types: Letter
Publication Status: ppublish
Abstract
Chronic active antibody-mediated rejection (caAMR) is a major cause of allograft loss after kidney transplantation (1). The BANFF 2013 classification redefined caAMR by the presence of donor-specific anti-HLA antibodies (DSA) together with immuno-histopathological evidence for active vascular lesions of the endothelium (C4d deposits, glomerulitis, peritubular capillaritis) as well as evidence of chronic tissue injury (transplant glomerulopathy, peritubular capillary basement membrane multilayering or arterial intimal fibrosis) (2,3). Humoral immunity, detected by the presence of DSA, and B cells are considered pivotal in the development of caAMR. Gosset et al. showed that circulating DSA are responsible for accelerated allograft fibrosis independently of acute AMR (1). This article is protected by copyright. All rights reserved.

Keywords
Adult, Female, Graft Rejection/drug therapy, Graft Rejection/immunology, Humans, Immunologic Factors/therapeutic use, Kidney Transplantation/adverse effects, Male, Middle Aged, Retrospective Studies, Rituximab/therapeutic use, Young Adult
Pubmed
Web of science
Open Access
Yes
Create date
16/01/2018 9:41
Last modification date
20/08/2019 16:40
Usage data